Resources

Filter by:

A bispecific nanobody for the treatment of von Willebrand disease type 1

Peyron I, Casari C, McCluskey G, Licari V, Bocquet E, Auditeau C, Daniel MY, Roullet S, Susen S, Christophe OD, Lenting PJ, & Denis CV

HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins

Oosterhoff JJ, Stam W, van Brummelen SR, Bentlage AEH, de Vos T, de Pereda JM, Porcelijn L, Kapur R, de Haas M, van der Schoot CE, Vidarsson G, & Margadant C